Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07013201 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

StatusRecruiting
PhasePhase 2
SponsorLEO Pharma
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 39 to 40
    • Eligibility criteria expanded, about 46 words
    • Secondary endpoints: details revised at 1 of 26 entries
  2. Study sites: 38 to 39v16
  3. Re-verified, no change to tracked fieldsv15
  4. Study sites: 37 to 38v14
  5. Study sites: 36 to 37v13
Show 11 earlier versionsHide 11 earlier versions
  1. Study sites: 35 to 36v12
  2. Study sites: 32 to 35v11
  3. Study sites: 27 to 32v10
  4. Study sites: 24 to 27v9
  5. Study sites: 21 to 24v8
  6. Study sites: 15 to 21v7
  7. Study sites: 5 to 15
    • Start date changed from estimate of Sep 1, 2025 to Sep 11, 2025
    v6
  8. Study sites: 3 to 5
    • Start date: Aug 2025 to Sep 1, 2025
    v5
  9. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 2 to 3
    • Start date: Jul 7, 2025 to Aug 2025
    v4
  10. Study sites: 0 to 2
    • Start date: Jun 16, 2025 to Jul 7, 2025
    v3
  11. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
LEO Pharma
25 trials monitored
See all monitored trials
Psoriasis
591 trials monitored
See 24 trials at risk
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants will be approximately 18 weeks, for an approximate total of 9 visits.
Trial Details
NCT Number NCT07013201
Lead Sponsor LEO Pharma
Conditions
(from sponsor)		 Palmoplantar Pustulosis
Related terms Psoriasis
Enrollment 135 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov